Quantitative histopathology and chromosome 9 polysomy in a clinical trial of 4-HPR

Gynecologic Oncology

Volumn 94, Issue 2, 2004, Pages 296-306

  Yamal, Jose Miguel ^a,b   Cox, Dennis ^b   Hittelman, Walter N ^a   Boiko, Iouri ^c   Malpica, Anais ^a   Guillaud, Martial ^d   MacAulay, Calum ^d   Follen, Michele ^a   Vlastos, Anne Therese ^a,e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Rice University   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d British Columbia Cancer Centre   (Canada)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

4 HPR; Cervical intraepithelial neoplasia; Chemoprevention; Chromosome 9 polysomy; Intermediate endpoint biomarkers; Quantitative histopathology

Indexed keywords

FENRETINIDE; PLACEBO;

ARTICLE; CHROMOSOME 9; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMETRY; DRUG EFFECT; FEMALE; FEULGEN STAINING; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZATION; STATISTICAL ANALYSIS; TISSUE SLICE; TREATMENT OUTCOME; TUMOR BIOPSY; UTERINE CERVIX DYSPLASIA;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; FENRETINIDE; HUMANS; UTERINE CERVICAL NEOPLASMS;

EID: 3543050044     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.04.030     Document Type: Article

References (22)

1. Moon R.C., Thompson H.J., Becci P.J., Grubbs C.J., Gander R.J., Newton D.L., et al. N-(4-hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res. 39:1979;1339-1346
2. Follen M. A clinical trial of 4-hydroxyphenylretinamide for the treatment of high grade squamous intraepithelial neoplasia. Dissertation. University of Michigan, 2000.
3. Oridate N., Suzuki S., Higuchi M., Mitchell M.F., Hong W.K., Lotan R. Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J. Natl. Cancer Inst. 89:1997;1191-1198
4. Dmitrovsky E. N-(4-hydroxyphenyl)retinamide activation of a distinct pathway signaling apoptosis. [editorial] J. Natl. Cancer Inst. 89:1997;1179-1181
5. Oridate N., Lotan D., Mitchell M.F., Hong W.K., Lotan R. Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: implications for chemoprevention. J. Cell. Biochem. Suppl. 23:1995;80-86
6. Lotan R., Trizna Z., Zou C.C., Lotan D., Mitchell M.F., Zou C.P. Additive inhibitory effects of retinoids and interferon-α on the growth of human cervical carcinoma cells: lack of association with HPV status or retinoid receptor expression. Int. J. Oncol. 8:1996;5-13
7. Kelloff G.J., Boone C.W., Crowell J.A., Steele V.E., Lubet R.A., Doody L.A., et al. New agents for cancer chemoprevention. J. Cell. Biochem. 26S:1996;1-28
8. Veronesi U., De Palo G., Marubini E., Costa A., Formelli F., Mariani L., et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst. 91:1999;1847-1856
9. Kurie J.M., Lee J.S., Khuri F.R., Mao L., Morice J.C., Lee J.J., et al. N-(hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of bronchial epithelium. Clin. Cancer Res. 6:2000;2973-2979
10. Kim J., Shin D.M., El-Naggar A., Lee J.S., Corrales C., Lippman S.M., et al. Chromosome polysomy and histological characteristics in oral premalignant lesions. Cancer Epidemiol. Biomarkers Prev. 10:2001;319-325
11. Follen M., Atkinson E.N., Malpica A., West L., Hittelman W.N., Lotan R., et al. A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. Clin. Cancer Res. 6:2001;3356-3365
12. Palcic B., Garner D.M., MacAulay C.E. Image cytometry and chemoprevention in cervical cancer. J. Cell. Biochem. Suppl. 23:1995;43-54
13. MacAulay C., Palcic B. Fractal texture features based on optical density surface area: use in image analysis of cervical cells. Anal. Quant. Cytol. Histol. 12:1990;394-398
14. Ihaka R., Gentleman R. R: a language for data analysis and graphics. J. Comput. Graph. Stat. 5:1996;299-314
15. Westfall P., Young S. Resampling based multiple testing. 1993;Wiley, New York
16. Breiman L., Friedman J.H. Estimating optimal transformations for multiple regression and correlations (with discussion). J. Am. Stat. Assoc. 80:1985;580-619
17. Good P. Permutation tests: a practical guide to resampling methods for testing hypotheses. 1994;Springer, New York
18. Guillaud M., Cox D., Adler-Storthz K., Malpica A., Staerkel G., Matisic J., et al. Exploratory analysis of quantitative histopathology of cervical intraepithelial neoplasia: objectivity, reproducibility, malignancy-associated changes, and human papillomavirus. Cytometry. 2003;. [In press]
19. Decensi A., Torrisi R., Polizzi A., Gesi R., Brezzo B., Rolando M., et al. Effect of the synthetic retinoid fenretinamide on dark adaptation and the ocular surface. J. Natl. Cancer Inst. 86:1994;105-110
20. Mehta R.G., Moon R.C., Hawthorne M., Formelli F., Costa A. Distribution of fenretinide in the mammary gland of breast cancer patients. Eur. J. Cancer. 27:1991;138-141
21. Mitchell M.F., Hittelman W.N., Hong W.K., Lotan R., Schottenfeld D. The natural history of cervical intraepithelial neoplasia: an argument for intermediate endpoint biomarkers. Cancer Epidemiol. Biomarkers Prev. 3:1994;619-626
22. Follen M., Vlastos A., Meyskens F.L. Jr., Atkinson E.N., Schottenfeld D. Why phase II trials in cervical chemoprevention are negative: what have we learned? Cancer Causes Control. 13:2002;855-873